WASHINGTON DC (March 12, 2019) — US Senate Finance Committee Chairman Charles "Chuck" Grassley of Iowa and Ranking Member Ron Wyden of Oregon today invited executives from five pharmacy benefit manager (PBMs) companies to testify before a committee hearing on Wednesday, April 3, 2019, on drug pricing in the United States, the third in a series of hearings examining prescription drug costs.
The companies invited include Cigna Corporation, CVS Caremark and CVS Health Corporation, Humana Inc, OptumRx, and Prime Therapeutics LLC.
“Middlemen in the health care industry owe patients and taxpayers an explanation of their role. There’s far too much bureaucracy and too little transparency getting in the way of affordable, quality health care,” Sens Grassley and Wyden said. “We’ve heard from pharmaceutical companies and it’s only fair that the committee has the opportunity to ask questions of other players in the health care supply chain. Every part of the industry has a role to play in lowering prescription drug prices. Witnesses from these companies should come prepared to provide real information and discuss real solutions.”
The Finance Committee held its first hearing on drug pricing on January 29 and its second hearing on drug pricing on February 26.
Links to the letters inviting the companies to testify can be found below.
CVS Caremark and CVS Health Corporation
The below witnesses have confirmed attendance:
Derica Rice
President and Executive Vice President
CVS Caremark and CVS Health Corporation
John Prince
Chief Executive Officer
OptumRx
Steven Miller, MD
Executive Vice President and Chief Clinical Officer
Cigna Corporation
Mike Kolar, JD
Interim President and CEO
Senior Vice President, General Counsel
Prime Therapeutics LLC
William Fleming, PharmD
Segment President, Healthcare Services
Humana Inc
